Cellectis publishes article in Frontiers in Immunology and reveals…

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) – Cellectis (the “Company”) CLLSa clinical-stage biotechnology company using its breakthrough gene-editing platform to develop life-saving cell and gene therapies, today published an article in Frontiers Bioengineering demonstrating the efficacy of its TALEN® engineered FAP-UCART cells in cancer-associated fibroblasts will ( CAF) depletion, reduction of desmoplasia and tumor […]

Merck Strengthens Immunology Pipeline with Prometheus Acquisition…

PRA023 is a novel candidate for late-stage ulcerative colitis and Crohn’s disease and other autoimmune diseases Prometheus Biosciences’ comprehensive data set enables target discovery and a precision medicine approach in the fields of inflammation and immunology RAHWAY, NJ and SAN DIEGO, April 16, 2023 (GLOBE NEWSWIRE) — Merck MRKknown as MSD outside the United States […]

GenScript and Gladstone-UCSF Institute of Genomic Immunology…

The study, published in Nature Biotechnology, describes methods using ssDNA donor templates to reduce cellular toxicity and achieve 40 percent knock-in editing efficiency with minimal cellular toxicity across a variety of primary cell types PISCATAWAY, NJ, September 22, 2022 /PRNewswire/ — GenScript United States of America inc., the world’s leading provider of life science research […]